Compare McKesson Corporation (MCK) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Ferrari NV — how do they compare? McKesson Corporation trades at $824.96 (market cap $97.35B), while Ferrari NV trades at $370.95 (market cap $65.48B). The key difference: McKesson Corporation is the larger of the two by market cap, and Ferrari NV pays the higher dividend (1.14%). Which is the better fit depends on your goals.
| MCK | RACE | |
|---|---|---|
Market Cap | $97.35B | $65.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $517.65 |
52-Week Low | $659.01 | $314.63 |
Enterprise Value | $101.98B | $66.69B |
Dividend Yield | 0.39% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Ferrari (RACE) trades at $371.52, down 1.41% on the day, with a bullish technical signal from moving averages. The company exhibits strong fundamentals, including a 22.19% net income margin and consistent earnings beats, with Q2 2026 results due July 30, 2026. Recent news highlights institutional buying, a share buyback program, and the debut of its first electric vehicle, though the Luce model received mixed initial reception.
The outlook remains positive given analyst consensus, with a $467.50 price target implying significant upside. Key risks include execution on the EV transition and high valuation multiples. The stock presents a growth opportunity driven by brand strength and pricing power, but investors should weigh near-term volatility around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
